A new step towards earlier detection of type 1 diabetes

Published in Diabetologia, International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes responds to a growing global challenge. The incidence of T1D is rising, while most people who develop the condition have no family history of it. The guidance sets out the questions health systems need to answer, including who should be screened, at what ages, how often screening should be repeated and how an initial positive result should be confirmed. 

Behind the technical language is a simple and deeply human goal, giving people more time, more understanding and more support before T1D becomes an emergency. No family should have to learn about this life-changing condition for the first time in crisis now there is a safe and responsible way to identify it earlier. 

For me, the significance of this paper is that it takes early detection into a different phase. It moves the conversation from possibility to practical planning. Now we need to understand what would make screening safe, trusted and useful for families, clinicians and health systems. 

Why this guidance is needed now

That distinction is crucial. Screening is not simply a question of whether a test exists. It is a question of whether there is a responsible system around that test, with clear information, confirmatory testing, clinical monitoring and care for people who may be living with uncertainty about their future with the condition long before symptoms appear. 

That is why consensus is so valuable. It gives clinicians, researchers and policymakers a shared starting point, while recognising that implementation will need to be tested carefully in different healthcare systems. 

It also reflects a shift in how the field is thinking about T1D. Early stage T1D can be identified before symptoms develop, creating an opportunity to monitor progression, reduce the risk of emergency diagnosis and help people understand the condition sooner. 

For families, that difference can be profound. It can mean hearing the words ‘type 1 diabetes’ in a planned conversation, sitting with a clinician, asking questions and understanding what comes next, rather than hearing them for the first time during a life-threatening emergency. 

What the paper recommends

The guidance recommends beginning screening in young children aged two to four, then screening again at ages six to eight and 10 to 15, if the prior test is negative. Aligning these tests with routine preventative healthcare visits could make screening easier to deliver at scale. It also states that every initial positive result should be confirmed with a second test before a diagnosis is made. 

This new guidance fills a gap. Breakthrough T1D’s 2024 consensus guidance set out how clinicians should monitor people once autoantibodies have been found. This latest work tackles the question that comes first. How do we find people in the early stages of type 1 diabetes in the general population? Together, the two papers provide a more complete route from screening to confirmation, monitoring and care. 

Here in the UK, we have a unique opportunity to demonstrate what is possible. The NHS gives us the potential to reach families at scale, connect screening with follow-up care, and create a pathway that is safe, consistent and equitable. 

What must happen now is that evidence must be turned into action by building on the research already under way and answering the delivery questions that will determine whether screening can be offered effectively. These include how it could be integrated into existing services, what workforce and laboratory capacity would be required, and how ongoing care could be funded and delivered sustainably. 

Answering those questions will help the UK move from demonstrating that screening works to showing what it takes to deliver it at scale, with lessons that could extend far beyond the UK. 

Getting this right is essential because screening is about more than clinical accuracy. It is about building trust. We must ensure families are informed, supported and able to understand what an early result means, and what comes next. 

Turning guidance into action

Breakthrough T1D’s role is to keep that conversation moving. We can bring together researchers, clinicians, policymakers and people affected by T1D so that decisions are led by evidence and shaped by lived experience. That is what this consensus paper represents. It is not the end of the debate, but a more mature and practical starting point for what comes next. 

We should be careful not to overstate what one paper can do. But we should also recognise when the ground has shifted. This guidance gives us a clearer basis for action and a chance to shape early detection in a way that is safe, equitable and centred on the people it is meant to help. 

Find out more about early detection screening for type 1 diabetes, including how it works and current screening opportunities.